Latest & greatest articles for chronic kidney disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on chronic kidney disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on chronic kidney disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for chronic kidney disease

201. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study.

Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. BACKGROUND: Diabetes is regarded as a coronary heart disease risk equivalent-ie, people with the disorder have a risk of coronary events similar to those with previous myocardial infarction. We assessed whether chronic kidney disease should be regarded as a coronary heart disease risk equivalent. METHODS: We studied a population-based cohort with measures (...) of estimated glomerular filtration rate (eGFR) and proteinuria from Alberta, Canada. We used validated algorithms based on hospital admission and medical-claim data to classify participants with baseline history of myocardial infarction or diabetes and to ascertain which patients were admitted to hospital for myocardial infarction during follow-up (the primary outcome). For our primary analysis, we defined baseline chronic kidney disease as eGFR 15-59·9 mL/min per 1·73 m(2) (stage 3 or 4 disease). We used

Lancet2012

202. Screening for, monitoring, and treatment of chronic kidney disease stages 1 to 3: a systematic review for the US Preventive services task force and for an american college of physicians clinical practice guideline

Screening for, monitoring, and treatment of chronic kidney disease stages 1 to 3: a systematic review for the US Preventive services task force and for an american college of physicians clinical practice guideline Screening for, monitoring, and treatment of chronic kidney disease stages 1 to 3: a systematic review for the US Preventive Services Task Force and for an American College of Physicians clinical practice guideline Screening for, monitoring, and treatment of chronic kidney disease (...) stages 1 to 3: a systematic review for the US Preventive Services Task Force and for an American College of Physicians clinical practice guideline Fink HA, Ishani A, Taylor BC, Greer NL, Macdonald R, Rossini D, Sadiq S, Lankireddy S, Kane RL, Wilt TJ CRD summary This review concluded that evidence for treatment benefit in chronic kidney disease was strongest for angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers and in patients with albuminuria combined with diabetes

DARE.2012

204. Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in chronic kidney disease before and during dialysis

Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in chronic kidney disease before and during dialysis Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in chronic kidney disease before and during dialysis Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in chronic kidney disease before and during dialysis Vegter S, Tolley K, Keith MS, Postma MJ Record Status This is a critical abstract of an economic (...) evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of the non-calcium-based phosphate binder lanthanum carbonate, as a second-line treatment for hyperphosphataemia, after the failure of calcium-based binders, for patients with chronic kidney disease who had

NHS Economic Evaluation Database.2012

205. Prevalence of chronic kidney disease in China: a cross-sectional survey.

Prevalence of chronic kidney disease in China: a cross-sectional survey. BACKGROUND: The prevalence of chronic kidney disease is high in developing countries. However, no national survey of chronic kidney disease has been done incorporating both estimated glomerular filtration rate (eGFR) and albuminuria in a developing country with the economic diversity of China. We aimed to measure the prevalence of chronic kidney disease in China with such a survey. METHODS: We did a cross-sectional survey (...) of a nationally representative sample of Chinese adults. Chronic kidney disease was defined as eGFR less than 60 mL/min per 1·73 m(2) or the presence of albuminuria. Participants completed a lifestyle and medical history questionnaire and had their blood pressure measured, and blood and urine samples taken. Serum creatinine was measured and used to estimate glomerular filtration rate. Urinary albumin and creatinine were tested to assess albuminuria. The crude and adjusted prevalence of indicators of kidney

Lancet2012

206. Chronic kidney disease stages 1?3: screening, monitoring, and treatment

Chronic kidney disease stages 1?3: screening, monitoring, and treatment Chronic kidney disease stages 1–3: screening, monitoring, and treatment. Chronic kidney disease stages 1–3: screening, monitoring, and treatment. Fink HA, Ishani A, Taylor BC, Greer NL, MacDonald, R, Rossini D, Sadiq S, Lankireddy S, Kane RL, Wilt TJ Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made (...) for the HTA database. Citation Fink HA, Ishani A, Taylor BC, Greer NL, MacDonald, R, Rossini D, Sadiq S, Lankireddy S, Kane RL, Wilt TJ. Chronic kidney disease stages 1–3: screening, monitoring, and treatment. Rockville: Agency for Healthcare Research and Quality (AHRQ). Comparative Effectiveness Review No. 37. 2012 Authors' objectives The objective was to systematically review and synthesize evidence regarding benefits and harms of screening for and monitoring and treatment of chronic kidney disease (CKD

Health Technology Assessment (HTA) Database.2012

207. Systematic review: Cochrane review: in adults with chronic kidney disease regular exercise improves physical fitness, walking capacity, heart rate and blood pressure and some nutritional parameters

Systematic review: Cochrane review: in adults with chronic kidney disease regular exercise improves physical fitness, walking capacity, heart rate and blood pressure and some nutritional parameters Cochrane review: in adults with chronic kidney disease regular exercise improves physical fitness, walking capacity, heart rate and blood pressure and some nutritional parameters | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies (...) . Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Cochrane review: in adults with chronic kidney disease regular exercise improves

Evidence-Based Nursing (Requires free registration)2012

209. Biomarkers for assessing and managing iron deficiency anemia in late-stage chronic kidney disease

Biomarkers for assessing and managing iron deficiency anemia in late-stage chronic kidney disease Biomarkers for assessing and managing iron deficiency anemia in late-stage chronic kidney disease Biomarkers for assessing and managing iron deficiency anemia in late-stage chronic kidney disease Chung M, Moorthy D, Hadar N, Salvi P, Iovin RC, Lau J Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality (...) of this assessment has been made for the HTA database. Citation Chung M, Moorthy D, Hadar N, Salvi P, Iovin RC, Lau J. Biomarkers for assessing and managing iron deficiency anemia in late-stage chronic kidney disease. Rockville: Agency for Healthcare Research and Quality (AHRQ). Comparative Effectiveness Review No. 83. 2012 Authors' objectives To summarize the literature on the use of newer versus classical laboratory biomarkers of iron status as part of the management strategies for iron deficiency in stages 3

Health Technology Assessment (HTA) Database.2012

211. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial.

Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. 22337679 2012 02 16 2012 02 16 2016 10 25 1538-3598 307 7 2012 Feb 15 JAMA JAMA Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. 674-84 10.1001/jama.2012.120 Vitamin D is associated with decreased cardiovascular-related morbidity and mortality, possibly by modifying cardiac (...) structure and function, yet firm evidence for either remains lacking. To determine the effects of an active vitamin D compound, paricalcitol, on left ventricular mass over 48 weeks in patients with an estimated glomerular filtration rate of 15 to 60 mL/min/1.73 m(2). Multinational, double-blind, randomized placebo-controlled trial among 227 patients with chronic kidney disease, mild to moderate left ventricular hypertrophy, and preserved left ventricular ejection fraction, conducted in 11 countries from

JAMA2012

212. Chronic Kidney Disease: Screening

Chronic Kidney Disease: Screening Inactive Topic - US Preventive Services Task Force JavaScript is required for this site to function properly. Please modify your browser settings to enable JavaScript. Search USPSTF Website Text size: Assembly version: 1.0.0.308 Last Build: 3/6/2018 4:20:40 PM You are here: Inactive Topic Chronic Kidney Disease: Screening Release Date: August 2012 The U.S. Preventive Services Task Force (USPSTF) has decided not to review the evidence and update its (...) recommendations for this topic. The previous evidence review and recommendation may contain information that is outdated. The USPSTF bases its recommendations on current evidence about preventive services. The USPSTF decides not to update some topics (or “inactivate” them) for a number of reasons. Topics may be inactivated because they are no longer relevant to clinical practice. This may be the result of changes in technology, a new understanding of the etiology or natural history of the disease

U.S. Preventive Services Task Force2012

213. KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease

KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease

National Kidney Foundation2012

215. Chronic kidney disease.

Chronic kidney disease. Chronic kidney disease is a general term for heterogeneous disorders affecting kidney structure and function. The 2002 guidelines for definition and classification of this disease represented an important shift towards its recognition as a worldwide public health problem that should be managed in its early stages by general internists. Disease and management are classified according to stages of disease severity, which are assessed from glomerular filtration rate (GFR (...) ) and albuminuria, and clinical diagnosis (cause and pathology). Chronic kidney disease can be detected with routine laboratory tests, and some treatments can prevent development and slow disease progression, reduce complications of decreased GFR and risk of cardiovascular disease, and improve survival and quality of life. In this Seminar we discuss disease burden, recommendations for assessment and management, and future challenges. We emphasise clinical practice guidelines, clinical trials

Lancet2011

216. The severity of acute kidney injury predicts progression to chronic kidney disease

The severity of acute kidney injury predicts progression to chronic kidney disease 21430640 2011 05 31 2011 09 16 2015 02 04 1523-1755 79 12 2011 Jun Kidney international Kidney Int. The severity of acute kidney injury predicts progression to chronic kidney disease. 1361-9 10.1038/ki.2011.42 Acute kidney injury (AKI) is associated with progression to advanced chronic kidney disease (CKD). We tested whether patients who survive AKI and are at higher risk for CKD progression can be identified (...) Am Soc Nephrol. 2007 Apr;18(4):1292-8 17314324 Clin J Am Soc Nephrol. 2006 Jan;1(1):43-51 17699189 Gend Med. 2008;5 Suppl A:S3-S10 18395681 J Am Soc Nephrol. 2009 Jan;20(1):223-8 19020007 Acute Kidney Injury complications diagnosis therapy Chi-Square Distribution Disease Progression Female Health Status Indicators Hospitalization Humans Kidney Failure, Chronic diagnosis etiology prevention & control Logistic Models Male Odds Ratio Patient Discharge Predictive Value of Tests Prognosis

EvidenceUpdates2011 Full Text: Link to full Text with Trip Pro

217. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease.

Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. CONTEXT: A high level of the phosphate-regulating hormone fibroblast growth factor 23 (FGF-23) is associated with mortality in patients with end-stage renal disease, but little is known about its relationship with adverse outcomes in the much larger population of patients with earlier stages of chronic kidney disease. OBJECTIVE: To evaluate FGF-23 as a risk factor for adverse (...) outcomes in patients with chronic kidney disease. DESIGN, SETTING, AND PARTICIPANTS: A prospective study of 3879 participants with chronic kidney disease stages 2 through 4 who enrolled in the Chronic Renal Insufficiency Cohort between June 2003 and September 2008. MAIN OUTCOME MEASURES: All-cause mortality and end-stage renal disease. RESULTS: At study enrollment, the mean (SD) estimated glomerular filtration rate (GFR) was 42.8 (13.5) mL/min/1.73 m(2), and the median FGF-23 level was 145.5 RU/mL

JAMA2011 Full Text: Link to full Text with Trip Pro

218. Aldosterone antagonists may prevent progression of chronic kidney disease

Aldosterone antagonists may prevent progression of chronic kidney disease PEARLS Practical Evidence About Real Life Situations PEARLS are succinct summaries of Cochrane Systematic Reviews for primary care practitioners. They Aldosterone antagonists may prevent progression of chronic kidney disease Clinical question How effective are aldosterone antagonists in patients with chronic kidney disease (CKD) currently treated with angiotensin converting enzyme inhibitors (ACEi) and angiotensin (...) used to reduce proteinuria and retard the progression of CKD. However, some patients do not attain complete resolution of proteinuria and might have higher aldosterone levels within a few months of treatment. The addition of aldosterone antagonists may be beneficial to these patients for reduction of progression of renal damage. Cochrane Systematic Review Navaneethan SD et al. Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Reviews 2009, Issue 3. Article

Cochrane PEARLS2011

219. Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier

Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier Upadhyay A, Earley A, Haynes SM, Uhlig K CRD summary This review did not find evidence that treatment to achieve a lower blood pressure target improved outcomes compared with a higher (...) target in adults with chronic kidney disease. Benefits were also uncertain for the subgroup of patients with proteinuria. Despite some limitations in the review methods and reporting, the authors' conclusions seem likely to be reliable. Authors' objectives To compare the effects of lower versus higher blood pressure targets in adults with chronic kidney disease and different levels of proteinuria. Searching MEDLINE and Cochrane Central Register of Controlled Trials (CENTRAL) were searched from July

DARE.2011

220. Prevention of contrast-induced nephropathy by bolus injection of sodium bicarbonate in patients with chronic kidney disease undergoing emergent coronary procedures

Prevention of contrast-induced nephropathy by bolus injection of sodium bicarbonate in patients with chronic kidney disease undergoing emergent coronary procedures 21349483 2011 04 04 2011 06 07 2016 11 25 1879-1913 107 8 2011 Apr 15 The American journal of cardiology Am. J. Cardiol. Prevention of contrast-induced nephropathy by bolus injection of sodium bicarbonate in patients with chronic kidney disease undergoing emergent coronary procedures. 1163-7 10.1016/j.amjcard.2010.12.012 We conducted (...) a prospective study to determine whether a bolus injection of sodium bicarbonate before emergent coronary procedures in patients with chronic kidney disease (CKD) might prevent contrast-induced nephropathy (CIN). We enrolled 59 patients with CKD, defined by a serum creatinine concentration of >1.1 mg/dl or an estimated glomerular filtration rate of <60 ml/min, who were scheduled at admission to undergo an emergent coronary procedure. The patients were randomized to receive a bolus intravenous injection

EvidenceUpdates2011